[The effect of low dose methotrexate treatment on bone mineral density in patients with rheumatoid arthritis]. 2002

Karol Kita, and Stanisław Sierakowski
Klinika Reumatologii i Chorób Wewnetrznych Akademii Medycznej w Białymstoku.

To evaluate the bone mineral density (BMD) in patients with rheumatoid arthritis (RA) treated with MTX or SF. The study consisted of 56 premenopausal women diagnosed with rheumatoid arthritis (RA). Bone mineral density (BMD) of the lower lumbar spine was assessed before starting treatment, and again after 12 months of treatment. DEXA scanning was used to evaluate BMD. Corticosteroids or other substances known to affect bone metabolism were not administered. 45 women completed the study, of whom 23 were treated using SF and 22 MTX. The average dosage of MTX used was calculated to be 590 mg. A significant difference in the BMD of SF and MTX patients was not observed in the pretreatment phase, nor after 12 months of treatment. However, in all patients a significant reduction of BMD was observed, irrelevant of the choice of drug. The average loss of bone mass was 1.7% and 1.4% in the MTX and SF groups, respectively. MTX therapy administered in low doses as assessed after 12 months did not cause a rapid decrease of bone density in patients with RA.

UI MeSH Term Description Entries
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D010024 Osteoporosis Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis. Age-Related Osteoporosis,Bone Loss, Age-Related,Osteoporosis, Age-Related,Osteoporosis, Post-Traumatic,Osteoporosis, Senile,Senile Osteoporosis,Osteoporosis, Involutional,Age Related Osteoporosis,Age-Related Bone Loss,Age-Related Bone Losses,Age-Related Osteoporoses,Bone Loss, Age Related,Bone Losses, Age-Related,Osteoporoses,Osteoporoses, Age-Related,Osteoporoses, Senile,Osteoporosis, Age Related,Osteoporosis, Post Traumatic,Post-Traumatic Osteoporoses,Post-Traumatic Osteoporosis,Senile Osteoporoses
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001172 Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. Rheumatoid Arthritis
D012460 Sulfasalazine A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907) Salicylazosulfapyridine,Asulfidine,Azulfadine,Azulfidine,Azulfidine EN,Colo-Pleon,Pleon,Pyralin EN,Salazopyrin,Salazosulfapyridine,Sulfasalazin medac,Sulfasalazin-Heyl,Sulfasalazine FNA,Sulphasalazine,Ucine,Ulcol,ratio-Sulfasalazine,Colo Pleon,Sulfasalazin Heyl,ratio Sulfasalazine
D015502 Absorptiometry, Photon A noninvasive method for assessing BODY COMPOSITION. It is based on the differential absorption of X-RAYS (or GAMMA RAYS) by different tissues such as bone, fat and other soft tissues. The source of (X-ray or gamma-ray) photon beam is generated either from radioisotopes such as GADOLINIUM 153, IODINE 125, or Americanium 241 which emit GAMMA RAYS in the appropriate range; or from an X-ray tube which produces X-RAYS in the desired range. It is primarily used for quantitating BONE MINERAL CONTENT, especially for the diagnosis of OSTEOPOROSIS, and also in measuring BONE MINERALIZATION. Absorptiometry, X-Ray,Dual-Photon Absorptiometry,Photodensitometry, X-Ray,Photon Absorptiometry,Single-Photon Absorptiometry,X-Ray Absorptiometry,Absorptiometry, Dual X-Ray,Absorptiometry, Dual-Energy Radiographic,Absorptiometry, Dual-Energy X-Ray,DEXA Scan,DPX Absorptiometry,DXA Scan,Densitometry, X-Ray,Densitometry, Xray,Dual X-Ray Absorptiometry,Dual-Energy Radiographic Absorptiometry,Dual-Energy X-Ray Absorptiometry,Dual-Energy X-Ray Absorptiometry Scan,Radiographic Absorptiometry, Dual-Energy,X-Ray Absorptiometry, Dual-Energy,X-Ray Photodensitometry,Absorptiometries, DPX,Absorptiometry, DPX,Absorptiometry, Dual Energy Radiographic,Absorptiometry, Dual Energy X Ray,Absorptiometry, Dual X Ray,Absorptiometry, Dual-Photon,Absorptiometry, Single-Photon,Absorptiometry, X Ray,DEXA Scans,DXA Scans,Densitometry, X Ray,Dual Energy Radiographic Absorptiometry,Dual Energy X Ray Absorptiometry,Dual Energy X Ray Absorptiometry Scan,Dual Photon Absorptiometry,Dual X Ray Absorptiometry,Photodensitometry, X Ray,Radiographic Absorptiometry, Dual Energy,Scan, DEXA,Scan, DXA,Scans, DEXA,Scans, DXA,Single Photon Absorptiometry,X Ray Absorptiometry,X Ray Absorptiometry, Dual Energy,X Ray Photodensitometry,X-Ray Absorptiometry, Dual,X-Ray Densitometry,Xray Densitometry
D015519 Bone Density The amount of mineral per square centimeter of BONE. This is the definition used in clinical practice. Actual bone density would be expressed in grams per milliliter. It is most frequently measured by X-RAY ABSORPTIOMETRY or TOMOGRAPHY, X RAY COMPUTED. Bone density is an important predictor for OSTEOPOROSIS. Bone Mineral Content,Bone Mineral Density,Bone Densities,Bone Mineral Contents,Bone Mineral Densities,Density, Bone,Density, Bone Mineral

Related Publications

Karol Kita, and Stanisław Sierakowski
September 2003, Rheumatology international,
Karol Kita, and Stanisław Sierakowski
August 1997, The Journal of rheumatology,
Karol Kita, and Stanisław Sierakowski
January 2000, Clinical and experimental rheumatology,
Karol Kita, and Stanisław Sierakowski
March 2005, Rheumatology international,
Karol Kita, and Stanisław Sierakowski
May 2014, Rheumatology (Oxford, England),
Karol Kita, and Stanisław Sierakowski
June 1995, The Journal of rheumatology,
Karol Kita, and Stanisław Sierakowski
November 1998, The Journal of rheumatology,
Karol Kita, and Stanisław Sierakowski
February 2003, Annals of the rheumatic diseases,
Karol Kita, and Stanisław Sierakowski
July 2002, Rheumatology (Oxford, England),
Karol Kita, and Stanisław Sierakowski
December 2023, Mediterranean journal of rheumatology,
Copied contents to your clipboard!